Comparing the Safety and Benefit of Natalizumab (Tysabri®) At-home Infusion vs At-hospital Infusion in Multiple Sclerosis

Active, not recruitingOBSERVATIONAL
Enrollment

279

Participants

Timeline

Start Date

June 14, 2021

Primary Completion Date

November 15, 2024

Study Completion Date

May 15, 2025

Conditions
Multiple Sclerosis (MS)
Interventions
OTHER

At-home natalizumab treated MS patient

"MS patient who are treated with natalizumab in at-home hospitalization (HAD) setting / according at-home hospitalization program"

Trial Locations (24)

13000

Marseille University Hospital, Marseille

29000

Quimper Hospital, Quimper

29200

Brest University Hospital, Brest

31000

Toulouse University Hospital, Toulouse

33000

Bordeaux University Hospital, Bordeaux

33500

Libourne Hospital, Libourne

34000

Montpellier University Hospital, Montpellier

35000

Rennes University Hospital, Rennes

37000

Tours University Hospital, Tours

38700

CHU Grenoble Alpes, La Tronche

40100

Dax Hospital, Dax

44000

Nantes University Hospital, Nantes

45000

Orléans Hospital, Orléans

59000

Lille University Hospital, Lille

59020

Hôpital St Vincent de Paul, Lille

67000

Strasbourg University Hospital, Strasbourg

75000

Adolphe de Rothschild Ophthalmological Foundation, Paris

AP-HP La Pitié-Salpêtrière Hospital, Paris

76000

Rouen University Hospital, Rouen

86000

Poitiers University Hospital, Poitiers

87000

Limoges University Hospital, Limoges

92140

Percy Army Training Hospital, Clamart

Unknown

CH Ajaccio, Ajaccio

Les Hôpitaux de Chartres, Chartres

All Listed Sponsors
collaborator

Rennes University Hospital

OTHER

lead

Nantes University Hospital

OTHER